Prof Mark Ledwidge
Adjunct Professor, The School of Medicine, University College Dublin
Biography:
Prof. Mark Ledwidge (BSc Pharm, PhD, DBS, MPSI) is Co-Founder/Director of the Heartbeat Trust, H&L Pharma and Solvotrin Therapeutics. He is also UCD Professor in the School of Medicine at University College Dublin (Adjunct). Following graduation as a pharmacist and completion of a PhD in pharmaceutics at Trinity College, Dublin with Elan Corporation, Mark worked for Baxter Healthcare and Servier Laboratories in technical and marketing roles. He completed a Diploma in Business Strategy before co-founding the Heartbeat Trust, H&L Pharma and Solvotrin Therapeutics. Solvotrin successfully launched its first product Active Iron in 2017 and is currently developing anti-inflammatory drugs with applications in cancer chemoprevention.
Research Interests:
Marks research interests include: prevention of heart failure; natriuretic peptide and fibrosis in left ventricular dysfunction; iron deficiency; genetic and epigenetic approaches for the management of cardiovascular disease; pharmacogenomics. He is inventor on a number of pending and granted patents. Mark is Co-Principal Investigator of the PARABLE study and the St Vincent’s Screening TO Prevent Heart Failure (STOP-HF) programme, which won a Royal College of General Practitioners Award in 2015 and has been incorporated into the 2017 American Heart Association/American College of Cardiology Guidelines.